This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation | MicrobiomeTrials
← Back to trials NCT05489523
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation Recruiting PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-05-01Est. Completion: 2027-05-31
Enrollment target: 25 participantsLocations Cedars-Sinai, Beverly Hills, California, United States Columbia University Medical Center, New York, New York, United States Cleveland Clinic, Cleveland, Ohio, United States UT Southwestern Medical Center, Dallas, Texas, United States Other microbiome trials you might be interested in Amyloidosis, Hereditary Amyloidosis Cardiac Amyloidosis, Familial Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy Transthyretin Gene Mutation
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substit…
New York, United States Est. completion Jun 30, 2027
Cardiac Amyloidosis
Cardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired…
Dijon, France Est. completion Jul 2028
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy hATTR-PN
The purpose of this study is to:
* Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the eff…
Aurora, United States Est. completion Dec 27, 2027